Delayed Haematological Toxicity in Patients Treated with 177Lu-octreotate Peptide Receptor Radiotherapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs)


Introduction: PRRT is associated with a high tumor control rate and early toxicity seems acceptable (haematological grade 3-4 toxicity: 11.3%). Long-term monitoring of haematological toxicity is unavailable.

Aim(s): To evaluate delayed haematological toxicity after PRRT for metastatic NETs.

Materials and methods: Twenty pts treated with 177-Lu PRRT between 2005 and 2013 for a progressive metastatic digestive NET (four courses every eight weeks, 7.9 GBq/injection) had prolonged follow-up with blood cell tests.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Hentic O, Lebtahi R, Kwekkeboom D, Fenaux P, Palazzo M,

Keywords: metastatic NET, PRRT, haematological toxicity,

To read the full abstract, please log into your ENETS Member account.